Suppr超能文献

氰基丙烯酸酯注射与β受体阻滞剂预防胃静脉曲张出血的一级预防:一项随机对照试验。

Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: a randomized controlled trial.

机构信息

Department of Gastroenterology, G B Pant Hospital, New Delhi, India.

出版信息

J Hepatol. 2011 Jun;54(6):1161-7. doi: 10.1016/j.jhep.2010.09.031. Epub 2010 Nov 5.

Abstract

BACKGROUND & AIMS: Gastric variceal bleeding is severe and is associated with high mortality. We compared the efficacy of cyanoacrylate injection and beta-blockers in primary prophylaxis of gastric variceal bleeding.

METHODS

Cirrhotics with large gastroesophageal varices type 2 with eradicated esophageal varices or large isolated gastric varix type 1, who had never bled from gastric varix, were randomised to cyanoacrylate injection (Group I, n=30), beta-blockers (Group II, n=29) or no treatment (Group III, n=30). Primary end-points were bleeding from gastric varix or death.

RESULTS

The actuarial probability of bleeding from gastric varices over a median follow-up of 26 months was 13% in Group I, 28% in Group II (p=0.039), and 45% in Group III (p=0.003). The actuarial probability of survival was higher in the cyanoacrylate compared to the no-treatment group (90% vs. 72%, p=0.048). The median hepatic venous pressure gradient (HVPG) was increased in Group I (14-15 mm Hg, p=0.001) and III (14-16 mm Hg, p=0.001) but decreased in Group II (14 to 12 mm Hg, p=0.001) during follow-up. Size of gastric varix >20 mm, a MELD score ≥17, and presence of portal hypertensive gastropathy predicted 'high risk' of first bleeding from gastric varices.

CONCLUSIONS

Primary prophylaxis is recommended in patients with large and high risk gastric varices to reduce the risk of first bleeding and mortality. Cyanoacrylate injection is more effective than beta-blocker therapy in preventing first gastric variceal bleeding.

摘要

背景与目的

胃静脉曲张出血严重,死亡率高。我们比较了氰基丙烯酸酯注射和β受体阻滞剂在胃静脉曲张出血一级预防中的疗效。

方法

肝硬化伴有已根除食管静脉曲张的大胃食管静脉曲张 2 型或大孤立性胃静脉曲张 1 型(无胃静脉曲张出血史)患者,随机分为氰基丙烯酸酯注射组(I 组,n=30)、β受体阻滞剂组(II 组,n=29)或无治疗组(III 组,n=30)。主要终点是胃静脉曲张出血或死亡。

结果

在中位随访 26 个月时,I 组胃静脉曲张出血的累计发生率为 13%,II 组为 28%(p=0.039),III 组为 45%(p=0.003)。与无治疗组相比,氰基丙烯酸酯组的生存率更高(90% vs. 72%,p=0.048)。I 组(14-15mmHg,p=0.001)和 III 组(14-16mmHg,p=0.001)的肝静脉压力梯度(HVPG)在随访期间升高,但 II 组(14 至 12mmHg,p=0.001)降低。胃静脉曲张大小>20mm、MELD 评分≥17 和存在门静脉高压性胃病预测胃静脉曲张首次出血的“高危”。

结论

建议对大且高危胃静脉曲张患者进行一级预防,以降低首次出血和死亡率的风险。氰基丙烯酸酯注射在预防胃静脉曲张首次出血方面比β受体阻滞剂治疗更有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验